Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Grazia Morandi

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Minerva Pediatrica|July 27, 2017
Short stature and high serum transaminase levels: growth hormone deficiency in a child with Becker muscular dystrophyRossella Gaudino, Claudia Piona, Grazia Morandi, et al.
Anticancer Research|May 6, 2021
Regorafenib-to-trifluridine/tipiracil Versus the Reverse Sequence for Refractory Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Real-life ExperienceCarlo Signorelli, Donatello Gemma, Roberta Grande, et al.
Current Oncology (Toronto, Ont.)|June 27, 2023
Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective StudyCarlo Signorelli, Maria Alessandra Calegari, Michele Basso, et al.
Cancers|December 23, 2023
Retrospective Correlation between First Drug Treatment Duration and Survival Outcomes in Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer: A Real-World Subgroup AnalysisCarlo Signorelli, Mario Giovanni Chilelli, Diana Giannarelli, et al.
Cancers|October 29, 2025
Real-World Evidence of Regorafenib Dose Escalation Versus Fixed Dosing in Refractory Metastatic Colorectal Cancer: Results from the ReTrITA StudyCarlo Signorelli, Michele Basso, Maria Alessandra Calegari, et al.
Cancers|June 26, 2025
Redefining the Use of Regorafenib and Trifluridine/Tipiracil Without Bevacizumab in Refractory Metastatic Colorectal Cancer: Findings from the ReTrITA StudyCarlo Signorelli, Maria Alessandra Calegari, Annunziato Anghelone, et al.
Current Oncology (Toronto, Ont.)|December 27, 2024
Survival Outcomes with Regorafenib and/or Trifluridine/Tipiracil Sequencing to Rechallenge with Third-Line Regimens in Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Subgroup Comparison from the ReTrITA StudyCarlo Signorelli, Maria Alessandra Calegari, Annunziato Anghelone, et al.
Pediatrics|October 13, 2023
Early Postnatal Infection of Neonates Born to Mothers Infected by SARS-CoV-2 Omicron VariantCarlo Pietrasanta, Andrea Ronchi, Massimo Agosti, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Minerva Pediatrica|July 27, 2017
Short stature and high serum transaminase levels: growth hormone deficiency in a child with Becker muscular dystrophyRossella Gaudino, Claudia Piona, Grazia Morandi, et al.
Anticancer Research|May 6, 2021
Regorafenib-to-trifluridine/tipiracil Versus the Reverse Sequence for Refractory Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Real-life ExperienceCarlo Signorelli, Donatello Gemma, Roberta Grande, et al.
Current Oncology (Toronto, Ont.)|June 27, 2023
Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective StudyCarlo Signorelli, Maria Alessandra Calegari, Michele Basso, et al.
Cancers|December 23, 2023
Retrospective Correlation between First Drug Treatment Duration and Survival Outcomes in Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer: A Real-World Subgroup AnalysisCarlo Signorelli, Mario Giovanni Chilelli, Diana Giannarelli, et al.
Cancers|October 29, 2025
Real-World Evidence of Regorafenib Dose Escalation Versus Fixed Dosing in Refractory Metastatic Colorectal Cancer: Results from the ReTrITA StudyCarlo Signorelli, Michele Basso, Maria Alessandra Calegari, et al.
Cancers|June 26, 2025
Redefining the Use of Regorafenib and Trifluridine/Tipiracil Without Bevacizumab in Refractory Metastatic Colorectal Cancer: Findings from the ReTrITA StudyCarlo Signorelli, Maria Alessandra Calegari, Annunziato Anghelone, et al.
Current Oncology (Toronto, Ont.)|December 27, 2024
Survival Outcomes with Regorafenib and/or Trifluridine/Tipiracil Sequencing to Rechallenge with Third-Line Regimens in Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Subgroup Comparison from the ReTrITA StudyCarlo Signorelli, Maria Alessandra Calegari, Annunziato Anghelone, et al.
Pediatrics|October 13, 2023
Early Postnatal Infection of Neonates Born to Mothers Infected by SARS-CoV-2 Omicron VariantCarlo Pietrasanta, Andrea Ronchi, Massimo Agosti, et al.
Pageof 2